Natural course of neuroblastoma detected by mass screening: A 5-year prospective study at a single institution

Journal of Clinical Oncology

Volumn 18, Issue 16, 2000, Pages 3012-3017

  Nishihira, Hirokazu ^a   Toyoda, Yasunori ^a   Tanaka, Yukichi ^a   Ijiri, Rieko ^a   Aida, Noriko ^a   Takeuchi, Maho ^a   Ohnuma, Kei ^a   Kigasawa, Hisato ^a   Kato, Keisuke ^a   Nishi, Toshiji ^a  

^a KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOVANILLIC ACID; VANILMANDELIC ACID;

ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; DECISION MAKING; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; SURGICAL RISK; TUMOR VOLUME; URINALYSIS;

EID: 0033890615     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.16.3012     Document Type: Article

References (31)

1. Complete pathologic maturation and regression of stage IV-S neuroblastoma without treatment
2. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy
3. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup?
4. A population-based study of neuroblastoma incidence, survival, and mortality in North America
5. Mass screening for neuroblastoma in infants in Japan
6. A population-based study of the usefulness of screening for neuroblastoma
7. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan
8. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children
9. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: A chromosome and N-myc amplification study
10. Spontaneous regression of neuroblastoma detected by mass screening
11. An observation program on neuroblastoma cases detected by mass screening at 6 months of age
12. Spontaneous regression of localized neuroblastoma detected by mass screening
13. Early detection of neuroblastoma in infants: Research? Yes. Routine screening? No
14. Report of the 1998 Consensus Conference on Neuroblastoma Screening
15. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents
16. Clinical and biological studies on 97 neuroblastoma cases
17. A proposed staging for children with neuroblastoma
18. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
19. Terminology and morphologic criteria of neuroblastic tumors: Recommendations by the International Neuroblastoma Pathology Committee
20. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
21. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma
22. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas
23. Clinicopathological study of mass-screened neuroblastoma with special emphasis on untreated observed cases: A possible histological clue to tumor regression
24. 10 years' neuroblastoma screening in Europe: Preliminary results of a clinical and biological review from the Study Group for Evaluation of Neuroblastoma Screening in Europe (SENSE)
25. Annual report on neuroblastoma mass screening in Japan: Report of the Committee on neuroblastoma
26. Surgical treatment of neuroblastomas in infants under 12 months of age
27. Is neuroblastoma screening evaluation needed and feasible?
28. Screening for neuroblastoma: 20 years and still no answer
29. Mass screening for neuroblastoma targeting children age 14 months in Sapporo City